This transcript has been edited for clarity.
Ileana L. Piña, MD, MPH: Hello. This is Ileana Piña from Central Michigan University with a special blog, because we're coming to you during the American College of Cardiology 2021 scientific sessions. This meeting is completely virtual for the second year in a row.
Early on Saturday, we attended the first set of late-breaker trials, and the very first presenter is with me today: my good friend, Marc Pfeffer, from the Brigham and Women's Hospital and Harvard Medical School. Marc has been a leader in clinical trials for many, many moons. Marc, as usual you continue to present wonderful work. I'm having a déjà vu of the SAVE and VALIANT trials, and I imagine you feel the same. Tell us about the trial you presented today, PARADISE-MI.
Marc A. Pfeffer, MD, PhD: For 30 years, patients who have had a myocardial infarction (MI) have benefited from drugs that inhibit the renin-angiotensin system. Angiotensin-converting enzyme (ACE) inhibitors reduce death and the development of heart failure. When angiotensin receptor blockers (ARBs) came out, there was a vigorous effort to see if these could do better than the ACE inhibitors, and they did. Valsartan was at least as good
Diabetes Confers Greater Excess Risk of Myocardial Infarction in Women Than Men
Aspirin Reduces Ischaemic Events in Patients With Pneumonia
Postinfarction Ventricular Septal Rupture
An Interview With PARADISE-MI PI Marc Pfeffer
Sacubitril/Valsartan: Trending Toward PARADISE Post MI?
Ileana L. Piña, MD, MPH; Marc A. Pfeffer, MD, PhD
DisclosuresMay 19, 2021
This transcript has been edited for clarity.
Ileana L. Piña, MD, MPH: Hello. This is Ileana Piña from Central Michigan University with a special blog, because we're coming to you during the American College of Cardiology 2021 scientific sessions. This meeting is completely virtual for the second year in a row.
Early on Saturday, we attended the first set of late-breaker trials, and the very first presenter is with me today: my good friend, Marc Pfeffer, from the Brigham and Women's Hospital and Harvard Medical School. Marc has been a leader in clinical trials for many, many moons. Marc, as usual you continue to present wonderful work. I'm having a déjà vu of the SAVE and VALIANT trials, and I imagine you feel the same. Tell us about the trial you presented today, PARADISE-MI.
Marc A. Pfeffer, MD, PhD: For 30 years, patients who have had a myocardial infarction (MI) have benefited from drugs that inhibit the renin-angiotensin system. Angiotensin-converting enzyme (ACE) inhibitors reduce death and the development of heart failure. When angiotensin receptor blockers (ARBs) came out, there was a vigorous effort to see if these could do better than the ACE inhibitors, and they did. Valsartan was at least as good
© 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ileana L. Piña, Marc A. Pfeffer. Sacubitril/Valsartan: Trending Toward PARADISE Post MI? - Medscape - May 19, 2021.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Ileana L. Piña, MD, MPH
Professor of Medicine, Wayne State University; Clinical Professor of Medicine, Central Michigan University; Director of CVD Research and Academic Affairs; Regional and National Director of Heart Failure, Detroit Medical Center, Detroit, Michigan
Disclosure: Ileana L. Piña, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, office, partner, employee, advisor, consultant, or trustee for: US Food and Drug Administration; Center for Devices and Radiological Health
Marc A. Pfeffer, MD, PhD
Distinguished Victor J. Dzau Professor, Department of Medicine, Harvard Medical School; Senior Member, Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
Disclosure: Marc A. Pfeffer, MD, PhD, has disclosed the following financial relationships:
Serve(d) as a consultant for: AstraZeneca; Boehringer Ingelheim; Eli Lilly; Alliance; Corvidia; DalCor; GlaxoSmithKline; Lexicon; National Heart, Lung, and Blood Institute
Received research grant from: Novartis